FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.

FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.

Item
http://www.wikidata.org/entity/Q34653123
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerAnti-angiogenic agents in metastatic colorectal cancerThe CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer--a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).Ziv-aflibercept in metastatic colorectal cancerEstablishment and characterization of cell lines from chromosomal instable colorectal cancer.FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.Targeted therapy in gastrointestinal malignancies.Management of colorectal cancer presenting with synchronous liver metastases.Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.The potential role of nintedanib in treating colorectal cancer.Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling.Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer.Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.and Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
P2860

FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.

Item
http://www.wikidata.org/entity/Q34653123
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
FOLFIRI-bevacizumab as first-l ...... alysis of 29 published trials.
@ast
FOLFIRI-bevacizumab as first-l ...... alysis of 29 published trials.
@en
FOLFIRI-bevacizumab as first-l ...... alysis of 29 published trials.
@nl
type
label
FOLFIRI-bevacizumab as first-l ...... alysis of 29 published trials.
@ast
FOLFIRI-bevacizumab as first-l ...... alysis of 29 published trials.
@en
FOLFIRI-bevacizumab as first-l ...... alysis of 29 published trials.
@nl
prefLabel
FOLFIRI-bevacizumab as first-l ...... alysis of 29 published trials.
@ast
FOLFIRI-bevacizumab as first-l ...... alysis of 29 published trials.
@en
FOLFIRI-bevacizumab as first-l ...... alysis of 29 published trials.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
FOLFIRI-bevacizumab as first-l ...... alysis of 29 published trials.
@en
P2093
P304
P31
P356
10.1016/J.CLCC.2013.04.006
P407
P433
P478
P577
P698
P921